<div id="readability-page-1"><p><span>TransMedics Group (NASDAQ:TMDX - Get Free Report)</span> had its price objective increased by equities research analysts at Canaccord Genuity Group  from $147.00 to $148.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has a &#34;buy&#34; rating on the stock. Canaccord Genuity Group's price target would suggest a potential upside of 21.27% from the stock's current price.</p><div><p><span></span><span>Get <strong>TransMedics Group</strong> alerts:</span></p></div><ul><li>Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in May</li></ul><p>TMDX has been the subject of a number of other research reports. Wall Street Zen upgraded shares of TransMedics Group from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, October 18th. Piper Sandler decreased their price target on TransMedics Group from $145.00 to $140.00 and set an &#34;overweight&#34; rating for the company in a report on Thursday, October 30th. Weiss Ratings  reaffirmed a &#34;hold (c)&#34; rating on shares of TransMedics Group in a research report on Wednesday, October 8th. Needham &amp; Company LLC increased their price objective on TransMedics Group from $148.00 to $166.00 and gave the company a &#34;buy&#34; rating in a report on Monday, December 8th. Finally, Stifel Nicolaus began coverage on TransMedics Group in a research note on Thursday, September 4th. They set a &#34;hold&#34; rating and a $115.00 target price for the company. Six investment analysts have rated the stock with a Buy rating and four have assigned  a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $144.25.</p><p><b>View Our Latest Report on TransMedics Group</b></p><h2>TransMedics Group Stock Down 2.4%</h2><ul><li>3 Medical Technology Stocks Outperforming in 2025</li></ul><p>Shares of TMDX traded down $3.00 during midday trading on Wednesday, hitting $122.05. The company had a trading volume of 471,370 shares, compared to its average volume of 1,196,944. TransMedics Group has a 1 year low of $55.00 and a 1 year high of $156.00. The firm has a market capitalization of $4.17 billion, a P/E ratio of 49.28 and a beta of 2.06. The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69. The company's 50-day simple moving average is $127.10 and its 200-day simple moving average is $123.00. </p><p>TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.37 by $0.29. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The company had revenue of $143.82 million during the quarter, compared to the consensus estimate of $145.33 million. During the same quarter in the previous year, the firm earned $0.12 earnings per share. The firm's quarterly revenue was up 32.2% on a year-over-year basis.  As a group, sell-side analysts expect that  TransMedics Group will post 1 EPS for the current year. </p><h2>Insider Buying and Selling at TransMedics Group</h2><ul><li>3 High-Growth Stocks Traders Love and Investors Should Watch</li></ul><p>In related news, CFO Gerardo Hernandez sold 920 shares of the company's stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $139.62, for a total value of $128,450.40. Following the completion of the sale, the chief financial officer owned 15,064 shares in the company, valued at $2,103,235.68. This represents a 5.76% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through the SEC website. Also, Director Edward M. Basile sold 4,142 shares of the stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $130.45, for a total transaction of $540,323.90. Following the sale, the director owned 2,866 shares of the company's stock, valued at approximately $373,869.70. This represents a 59.10% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 13,062 shares of company stock valued at $1,797,634. 7.00% of the stock is currently owned by insiders. </p><h2>Institutional Trading of TransMedics Group</h2><p>Several hedge funds and other institutional investors have recently made changes to their positions in the company. Opal Wealth Advisors LLC purchased a new position in  TransMedics Group during the second quarter worth about $26,000.  Whittier Trust Co. of Nevada Inc. boosted its holdings in  TransMedics Group by 981.0% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company's stock valued at $26,000 after purchasing an additional 206 shares in the last quarter.  Salomon &amp; Ludwin LLC acquired a new position in  TransMedics Group during the 3rd quarter worth approximately $28,000.  Harvest Fund Management Co. Ltd purchased a new position in shares of  TransMedics Group during the 3rd quarter worth approximately $29,000.  Finally, Smartleaf Asset Management LLC lifted its holdings in shares of  TransMedics Group by 44.3% in the 1st quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock valued at $30,000 after buying an additional 135 shares during the period. Hedge funds and other institutional investors own  99.67% of the company's stock. </p><h2>About TransMedics Group</h2> (Get Free Report)<p>TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than TransMedics Group</li><li>Why Special Dividends Can be a Delightful Surprise for Income Investors</li><li>Can Upwork Maintain Its Comeback? Reasons to Be Bullish and Bearish</li><li>Uptrend Stocks Explained: Learn How to Trade Using Uptrends</li><li>Is Tesla Overvalued? 2 Reasons It Might Be a Bargain</li><li>CD Calculator: Certificate of Deposit Calculator </li><li>How These 2 Stocks Won 2025's AI Race—And What's In Store for 2026</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE1EWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE1EWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in TransMedics Group Right Now?</h2><p>Before you consider TransMedics Group, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TransMedics Group wasn't on the list.</p><p>While TransMedics Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

TMDX

<p>Canaccord Genuity Group raised its target price for TransMedics Group (NASDAQ:TMDX) from $147.00 to $148.00 and maintained a "buy" rating, suggesting a potential 21.27% upside. Other analysts have mixed ratings, with some downgrading and others upgrading their ratings. The stock has a consensus rating of "Moderate Buy" and an average price target of $144.25. Recent insider trading includes sales by the CFO and a director. The company reported strong quarterly earnings, with a 32.2% year-over-year revenue increase.</p>

TransMedics Group (NASDAQ:TMDX) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says